EP0169672B1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Method for producing transgenic animals
Assignee: Harvard University
•
Filing: 1985-06-24
•
Granted: 1992-05-13
•
Expires: 2005-06-24
Abstract
Abstract A method for producing a transgenic eucaryotic animal having an increased probability of developing neoplasms, said method comprising introducing into an animal embryo an activated oncogene sequence. The animal may be used in testing a material suspected of being carcinogenic or of conferring protection against carcinogens.
Inventors
- 👤 Philip Leder
- 👤 Timothy A. Stewart
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-26 00:31
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/63; C12N15/79; C12N15/85; C12N15/8509; A; A01; A01K; A01K67/00; A01K67/027; A01K67/0275; C07; C07K; C07K14/00; C07K14/005; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/5005; G01N33/5008; G01N33/5014; G01N33/5017; G01N33/53; G01N33/575; G01N33/57575; A01K2217/00; A01K2217/05; A01K2217/20; A01K2227/00; A01K2227/10; A01K2227/105; A01K2267/00; A01K2267/03; A01K2267/0331; A01K2267/0393; C12N2740/00; C12N2740/00011; C12N2740/10011; C12N2740/11011; C12N2740/11022
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
33 words
A method for producing a transgenic non-human mammalian animal having an increased probability of developing neoplasms, said method comprising chromosomally incorporating an activated oncogene sequence into the genome of a non-human mammalian animal.
Claim 2
Dependent Claim
28 words
A method as claimed in claim 1 wherein the chromosome of the animal includes an endogenous coding sequence substantially the same as the coding sequence of the oncogene.
Claim 3
Dependent Claim
31 words
A method as claimed in claim 2 wherein said oncogene sequence is integrated into a chromosome of said animal at a site different from the location of said endogenous coding sequence.
Claim 4
Dependent Claim
37 words
A method as claimed in claim 2 or claim 3 wherein transcription of said oncogene sequence is under the control of a promoter sequence different from the promoter sequence controlling the transcription of said endogenous coding sequence.
Claim 5
Independent Claim
24 words
A method as claimed in any one of claims 2 to 4 wherein said promoter sequence controlling transcription of said oncogene sequence is inducible.
Claim 6
Independent Claim
34 words
A method as claimed in any one of claims 1 to 4 wherein said activated oncogene sequence comprises a fused gene comprising an oncogene sequence fused to an activating viral or synthetic promotor sequence.
Claim 7
Dependent Claim
24 words
A method as claimed in claim 6 wherein said viral promoter sequence comprises a sequence selected either from an MMTV or an RSV promoter.
Claim 8
Independent Claim
25 words
A method as claimed in any one of claims 1 to 7 wherein said oncogene sequence comprises a coding sequence of a c- myc gene.
Claim 9
Independent Claim
61 words
A method as claimed in any one of claims 1 to 7 wherein said activated oncogene sequence comprises a DNA sequence selected from the oncogenes src, yes, fps, abl, ros, fgr, erbB, fms, mos, raf, Ha-ras-1, Ki-ras 2, Ki-ras 1, myc, myb, fos, ski, rel, sis, N-myc, N-ras, Blym, mam, neu, erbAl, ra-ras, mht-myc, myc, myb-ets, raf-2, raf-1, Ha-ras-2, or erbB.
Claim 10
Independent Claim
21 words
A method as claimed in any one of claims 1 to 8 wherein said activated oncogene is derived from a plasmid.
Claim 11
Dependent Claim
14 words
A plasmid selected from the group comprising plasmids ATCC 39745, 39746, 39747, 39748, 39749.
Claim 12
Dependent Claim
22 words
A method as claimed in claim 1 wherein the activated oncogene sequence is derived from a plasmid as defined in claim 11.
Claim 13
Independent Claim
26 words
A method as claimed in any one of claims 1 to 12 wherein said chromosomal incorporation is at a stage no later than the 8-cell stage.
Claim 14
Independent Claim
26 words
A method as claimed in any one of claims 1 to 12 wherein said chromosomal incorporation is at a stage no later than the 1-cell stage.
Claim 15
Dependent Claim
28 words
A method as claimed in claim 1 which comprises injecting into the male pronucleus of a fertilized one-cell mouse egg a linearized plasmid as defined in claim 11.
Claim 16
Independent Claim
40 words
A method of testing a material suspected of being a carcinogen which comprises exposing an animal produced according to the method of any one of claims 1 to 15 to said material and detecting neoplasms as an indication of carcinogenicity.
Claim 17
Independent Claim
57 words
A method of testing a material suspected of conferring protection against the development of neoplasms, said method comprising treating an animal produced according to the methods of any one of claims 1 to 15 with said material and detecting a reduced incidence of development of neoplasms, compared to an untreated animal, as an indication of said protection.
Claim 18
Dependent Claim
30 words
A method as claimed in claim 17, further comprising exposing said treated and untreated animals to a carcinogen prior to, after or simultaneously with treating said animals with said material.
Claim 19
Dependent Claim
51 words
A transgenic non-human mammalian animal whose germ cells and somatic cells contain an activated oncogene sequence as a result of chromosomal incorporation into the animal genome, or into the genome of an ancestor of said animal, said oncogene optionally being further defined according to any one of claims 3 to 10.
Claim 20
Dependent Claim
11 words
An animal as claimed in claim 19 which is a rodent.
Claim 21
Dependent Claim
24 words
An animal as claimed in claim 19 or claim 20 wherein said chromosomal incorporation is at a stage no later than the 8-cell stage.
Claim 22
Dependent Claim
24 words
An animal as claimed in claim 19 or claim 20 wherein said chromosomal incorporation is at a stage no later than the 1-cell stage.
Claim 23
Dependent Claim
24 words
A chromosome of an animal as claimed in claim 19, which comprises an oncogene as defined in any one of claims 3 to 10.
Claim 24
Independent Claim
30 words
A method of providing a cell culture comprising providing a transgenic non-human mammalian animal as defined in any one of claims 19 to 22 and culturing a somatic cell thereof.
Claim 25
Dependent Claim
24 words
A cell derived from a somatic cell obtained from a transgenic non-human mammalian animal as defined in any one of claims 19 to 22.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.